Hikma Pharma buys minority stake in Hubei Haosun
With this acquisition, Hikma intends to strengthen its API sourcing and R&D capabilities in key product areas. The deal allows Hikma to get license to Haosun’s APIs particularly
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.